When was WaveBreak founded?

WaveBreak was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is WaveBreak located?

WaveBreak is headquartered in Cambridge, United Kingdom.

Which legal entities is WaveBreak associated with?

WaveBreak is associated with WAVEBREAK THERAPEUTICS LIMITED and 1 other.

How many employees does WaveBreak have?

As of Jul 31, 2026, the latest employee count at WaveBreak is 7.

Is WaveBreak a funded company?

WaveBreak is a funded company, having raised a total of $64.3M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 06, 2016.

How much is WaveBreak worth?

The latest valuation of WaveBreak is £***** as of Apr 02, 2024.

When was the latest funding round of WaveBreak?

WaveBreak's latest funding was a $***** Series A round on Apr 02, 2024, with participation from 0 investor.

Where does WaveBreak rank among its competitors?

WaveBreak ranks 181st amongst 700 active competitors, of which 250 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of WaveBreak?

WaveBreak's top competitors include Sana Biotechnology, Denali Therapeutics and Fulcrum Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

WaveBreak - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of small molecule therapeutics for neurological disorders. It offers drugs that targets the fleeting protein intermediates, the oligomers to treat Parkinson’s disease, Alzheimer’s disease, and ALS.

Website: wavebreaktx.com
Email ID: *****@wavebreaktx.com

Key Metrics

Founded Year

2016

Location

Cambridge, United Kingdom

Stage

Series A

Total Funding

$64.3M in 6 rounds

Latest Funding Round

Series A, Apr 02, 2024, $*****

Post Money Valuation

£***** as on Apr 02, 2024

Investors

The Baupost Group & 11 more

Ranked

181^st among 700 active competitors

Employee Count

7 as on Jul 31, 2026

Similar Companies

Sana Biotechnology & 870 more

View WaveBreak's full profile

WaveBreak is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Wren Therapeutics Limited CIN: 10054518 , United Kingdom, Active	Mar 09, 2016	-	39 (As on Dec 31, 2020)
WAVEBREAK THERAPEUTICS LIMITED CIN: 10054518 , United Kingdom, Active	Mar 09, 2016	-	-

WaveBreak has raised a total funding of $64.3M over 6 rounds. Its first funding round was on May 06, 2016. WaveBreak has 12 institutional investors.

Here is the list of recent funding rounds of WaveBreak:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 02, 2024	6757385	Series A	6609152	3952238	5031626	9016352
Feb 08, 2021	5868865	Series A	2153121	3529175	3895646	9416588
Dec 17, 2020	7357467	Series A	1324829	2226047	4290805	9609376

Access funding benchmarks and valuations. Sign up today!

View details of WaveBreak's funding rounds and investors

WaveBreak's employee count trend

WaveBreak has 7 employees as of Jul 26. Here is WaveBreak's employee count trend over the years:

Uncover WaveBreak's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of WaveBreak include Sana Biotechnology, Denali Therapeutics and Fulcrum Therapeutics. Here is the list of Top 10 competitors of WaveBreak, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
2nd	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
3rd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
4th	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
5th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
6th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Bain Capital, Redmile Group & 17 others	67/100
7th	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	Bain Capital Life Sciences, RTW Investments ... & 12 others	65/100
8th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
9th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Humboldt Fund, 8VC & 7 others	65/100
10th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	ATW Partners, Sanofi & 6 others	65/100
181st	WaveBreak 2016, Cambridge (United Kingdom), Series A	Developer of small molecule therapeutics for neurological disorders	$64.3M	The Baupost Group, University of Cambridge ... & 10 others	43/100